Searchable abstracts of presentations at key conferences in endocrinology

ea0077p195 | Metabolism, Obesity and Diabetes | SFEBES2021

Diabetes and Young COVID: A two country and two wave study of associations

Sharma Bhavna , Sharma Angelica , Sharma Indu

Authors agree that although mortality for COVID 19 is low, comorbidities may contribute to severe disease and mortality. Chinese center for disease control and prevention reported three times higher mortality in patients with diabetes. However, most studies do not take into account age of patients. Our study aimed to evaluate association of COVID in patients lesser than 65 years of age in two countries, India and United Kingdom with diabetes. We excluded patients with co-morbi...

ea0086p161 | Adrenal and Cardiovascular | SFEBES2022

Prednisolone replacement therapy in Adrenal Insufficiency: Defining target ranges and timing for optimum Prednisolone level sampling

Sharma Angelica , Lazarus Katharine , Choudhury Sirazum , Meeran Karim

Introduction: Glucocorticoid replacement in adrenal insufficiency may be achieved by administering thrice- daily hydrocortisone or once-daily very low dose (2-4 mg) prednisolone. Prednisolone’s longer half-life enables once-daily dosing, improving patient satisfaction and compliance. At very low doses, it has shown no difference in most markers of metabolic risk when compared with hydrocortisone. At Imperial College Healthcare NHS Trust (ICHNT), use of an eight-hour troug...

ea0086p162 | Adrenal and Cardiovascular | SFEBES2022

5mg of Prednisolone results in over-replacement in individuals with Adrenal Insufficiency

Sharma Angelica , Lazarus Katharine , Choudhury Sirazum , Meeran Karim

Introduction: Liberal glucocorticoid replacement therapy prevents Addisonian crises in individuals with adrenal insufficiency (AI). Prednisolone is six to eight times more potent than hydrocortisone. There is inter-individual variation in glucocorticoid metabolism wherein 5 mg prednisolone once-daily may result in over-replacement in most individuals, with subsequent long-term morbidity and mortality.Methods: Data from individuals on established predniso...

ea0090p366 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Assessing Foundation Doctors knowledge on the use of Sodium-glucose cotransporter 2 (SGLT2) Inhibitors: A Quality Improvement Project

Haddad Aiman , Sharma Angelica , Lee Tse Tsz , Taufik Bara , Seetho Ian

Introduction: Sodium Glucose Co-transporter 2 inhibitors (SGLT2i) are a novel class of glucose-lowering therapies that have demonstrated prognostic benefit in the management diabetes, heart failure and renal impairment. National Institute for Health and Clinical Excellence (NICE) guidance recommends offering SGLT2i, in addition to metformin, first-line in individuals with type 2 diabetes (T2D) and chronic heart failure/ established atherosclerotic cardiovascular disease. Howev...

ea0099oc12.4 | Oral Communications 12: Diabetes, Obesity, Metabolism and Nutrition | Part II | ECE2024

Characteristics and outcomes of DKA in people taking SGLT2 inhibitors: DEKODE study

Mathur Nitish , Sharma Angelica , Philip Nevil , Rengarajan Lakshmi , Bomphrey Lucy , Abraham Anu , Saraf Sanjay , Dhatariya Ketan , Kempegowda Punith , Working Group Dekode

Background: Although SGLT2 inhibitors (SGLT2-i) have revolutionised the management of diabetes, they are associated with an increased risk of developing diabetic ketoacidosis (DKA). However, there remains a paucity of evidence about the risk factors, management, and outcomes of DKA episodes associated with SGLT2-i therapy. Improved understanding of these factors in order to optimise education, minimise risk, and improve outcomes of DKA episodes in individuals receiving SGLT2-i...